By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Advaxis, Inc. 

The Technology Centre of New Jersey
675 U.S. Route One, South
North Brunswick  New Jersey  08902   U.S.A.
Phone: 732-545-1590 Fax: 732-545-1084



Company News
Advaxis (ADXS)’ AXAL Receives Fast Track Designation By The FDA As Adjuvant Therapy For High-Risk Locally Advanced Cervical Cancer Patients 7/21/2016 8:06:22 AM
European Medicines Agency Committee Classifies Advaxis (ADXS)’ Axalimogene Filolisbac As An Advanced-Therapy Medicinal Product 7/18/2016 8:44:11 AM
Advaxis (ADXS) Appoints Ranya Dajani As Vice President, Corporate Development 7/12/2016 7:56:45 AM
Advaxis (ADXS) To Present At Cantor Fitzgerald’s 2nd Annual Healthcare Conference 7/8/2016 10:17:34 AM
FDA Grants Special Protocol Assessment to Advaxis (ADXS)’ Phase III Study Of AXAL In Patients With Cervical Cancer 7/6/2016 7:46:52 AM
Advaxis (ADXS) To Present At The 3rd Annual Jefferies Immuno-Oncology Summit 4/4/2016 8:37:37 AM
FDA Lifts Advaxis (ADXS) Clinical Hold 12/16/2015 11:44:15 AM
Advaxis (ADXS) Receives Orphan Drug Designation In The European Union For ADXS-HER2 For The Treatment Of Osteosarcoma 12/1/2015 10:43:56 AM
Advaxis (ADXS) To Receive $1.6 Million Through New Jersey Technology Business Tax (NOL) Program 11/17/2015 11:42:00 AM
Advaxis (ADXS) Presents New Data Featuring Its Lm Technology At The Society For Immunotherapy Of Cancer 2015 Annual Meeting 11/9/2015 12:21:41 PM